The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control
Open accessAbstract
Since December 2019, the novel coronavirus, SARS-CoV-2, has garnered global attention due to its rapid transmission, which has infected more than two million people worldwide. Early detection of SARS-CoV-2 is one of the crucial interventions to control virus spread and dissemination. Molecular assays have been the gold standard to directly detect for the presence of viral genetic material in infected individuals. However, insufficient viral RNA at the point of detection may lead to false negative results. As such, it is important to also employ immune-based assays to determine one's exposure to SARS-CoV-2, as well as to assist in the surveillance of individuals with prior exposure to SARS-CoV-2. Within a span of 4 months, extensive studies have been done to develop serological systems to characterize the antibody profiles, as well as to identify and generate potentially neutralizing antibodies during SARS-CoV-2 infection. The vast diversity of novel findings has added value to coronavirus research, and a strategic consolidation is crucial to encompass the latest advances and developments. This review aims to provide a concise yet extensive collation of current immunoassays for SARS-CoV-2, while discussing the strengths, limitations and applications of antibody detection in SARS-CoV-2 research and control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246 · cited 1×
“As the reported incubation period varies among different patient cohorts, it is often difficult to ascertain the actual day of onset, and infected subjects who are asymptomatic or pre-symptomatic may go undetected (5) (6) (7) .”
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,810
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Coronavirus envelope protein: current knowledge
Schoeman, D., & Fielding, B. C. (2019) · Virology Journal · doi:10.1186/s12985-019-1182-0 · Cited by 2,074
Xie, X., Zhong, Z., Zhao, W., Zheng, C., Wang, F., & Liu, J. (2020) · Radiology · doi:10.1148/radiol.2020200343 · Cited by 1,960 · cited 1×
“Apart from being costly and time consuming to perform, false negative results may arise due to improper handling of nucleic acid samples, inadequate and variable sampling resulting in insufficient viral genetic material at the point of detection (after 14 days pio), or biological variation on when viral RNA is detecta…”
BackgroundA serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654 · cited 3×
“A substantial level of cross-reactivity by SARS-CoV RBD-induced antibodies to SARS-CoV-2 RBD was described (Table 1) (20).”
BackgroundOkba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Viral load of SARS-CoV-2 in clinical samples.
Pan, Y., Zhang, D., Yang, P., Poon, L. L. M., & Wang, Q. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30113-4 · Cited by 1,562 · cited 2×
“SARSCoV-2 viral RNA has been detected in both throat and nasal swabs of infected individuals by qRT-PCR, which becomes almost undetectable by 14 days post-illness onset (pio) (or symptom onset) (8, 9) (Figure 2).”
BackgroundTian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
Koczula, K. M., & Gallotta, A. (2016) · Essays in Biochemistry · doi:10.1042/ebc20150012 · Cited by 1,147
A human monoclonal antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B.-J. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,132
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · Viruses · doi:10.3390/v12030254 · Cited by 1,116
ViPR: an open bioinformatics database and analysis resource for virology research
Pickett, B. E., Sadat, E. L., Zhang, Y., Noronha, J. M., Squires, R. B., Hunt, V., Liu, M., Kumar, S., Zaremba, S., Gu, Z., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr859 · Cited by 696
Nicholson, L. B. (2016) · Essays in Biochemistry · doi:10.1042/ebc20160017 · Cited by 623
Zhang, B., Zhou, X., Zhu, C., Song, Y., Feng, F., Qiu, Y., Feng, J., Jia, Q., Song, Q., Zhu, B., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00157 · Cited by 528
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H., Richardus, J. H., Liu, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903490 · Cited by 496 · cited 1×
“In addition, an earlier report has demonstrated waning of SARS-CoV-specific antibodies, therefore being undetectable in 91% of patient serum samples after 6 years (31) .”
BackgroundDeDiego, M. L., Álvarez, E., Almazán, F., Rejas, M. T., Lamirande, E., Roberts, A., Shieh, W.-J., Zaki, S. R., Subbarao, K., & Enjuanes, L. (2007) · Journal of Virology · doi:10.1128/jvi.01467-06 · Cited by 438
Meo, S. A., Alhowikan, A. M., Al-khlaiwi, T., Meo, I. M. U., Halepoto, D. M., Iqbal, M., Usmani, A. M., Hajjar, W. M., & Ahmed, N. (2020) · PubMed · doi:10.26355/eurrev_202002_20379 · Cited by 426
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
Lv, H., Wu, N. C., Tsang, O. T.-Y., Yuan, M., Perera, R. A. P. M., Leung, W. S., So, R. T. Y., Chan, J. M. C., Yip, G. K., Chik, T. S. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107725 · Cited by 407
Corman, V. M., Albarrak, A. M., Omrani, A. S., Albarrak, M. M., Farah, M. E., Almasri, M., Muth, D., Sieberg, A., Meyer, B., Assiri, A. M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ951 · Cited by 374
SARS-CoV-2: virus dynamics and host response
Chen, Y., & Li, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30235-8 · Cited by 286
Hsueh, P.-R., Huang, L.-M., Chen, P.-J., Kao, C.-L., & Yang, P.-C. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01009.x · Cited by 261
Profile of specific antibodies to SARS-CoV-2: The first report
Xiao, A. T., Gao, C., & Zhang, S. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.012 · Cited by 245
New SARS-like virus in China triggers alarm
Cohen, J., & Normile, D. (2020) · Science · doi:10.1126/science.367.6475.234 · Cited by 235
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227
Cutts, F. T., & Hanson, M. (2016) · Tropical Medicine & International Health · doi:10.1111/tmi.12737 · Cited by 176
Elshabrawy, H. A., Coughlin, M. M., Baker, S. C., & Prabhakar, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050366 · Cited by 172
Rajendran, M., Nachbagauer, R., Ermler, M. E., Bunduc, P., Amanat, F., Izikson, R., Cox, M. M. J., Palese, P., Eichelberger, M. C., & Krammer, F. (2017) · mBio · doi:10.1128/mbio.02281-16 · Cited by 165
Nachbagauer, R., Choi, A., Izikson, R., Cox, M. M. J., Palese, P., & Krammer, F. (2016) · mBio · doi:10.1128/mbio.01996-15 · Cited by 151
Antibody Response and Disease Severity in Healthcare Worker MERS Survivors
Alshukairi, A. N., Khalid, I., Ahmed, W., Dada, A. M., Bayumi, D. T., Malic, L. S., Althawadi, S., Ignacio, K. H., Alsalmi, H., Al-Abdely, H. M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2206.160010 · Cited by 141
Gorse, G. J., Donovan, M. M., & Patel, G. B. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25715 · Cited by 134
Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome
Lee, N. L. S., Chan, P. K. S., Ip, M., Wong, E., Ho, J., Ho, C., Cockram, C. S., & Hui, D. S. C. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2005.07.005 · Cited by 121
Berry, J. D., Hay, K. A., Rini, J. M., Yu, M., Wang, L., Plummer, F. A., Corbett, C. R., & Andonov, A. P. (2010) · mAbs · doi:10.4161/mabs.2.1.10788 · Cited by 111
Identification of an epitope of SARS-coronavirus nucleocapsid protein
Lin, Y. C., Shen, X., Rui Fu, Y. A. N. G., Li, Y. X., Ji, Y., He, Y., Shi, M., Lü, W., Shi, T. L., Wang, J., et al. (2003) · Cell Research · doi:10.1038/sj.cr.7290158 · Cited by 107
Chan, C.-M., Tse, H., Wong, S. S. Y., Woo, P. C. Y., Lau, S. K. P., Chen, L., Zheng, B. J., Huang, J., & Yuen, K. (2009) · Journal of Clinical Virology · doi:10.1016/j.jcv.2009.02.011 · Cited by 92
Immunofluorescence Assay for Serologic Diagnosis of SARS
Chan, P. K. S., Ng, K.-C., Chan, R. C. W., Lam, R. K. Y., Chow, V. C. Y., Hui, M., Wu, A. K., Lee, N. L. S., Yap, F. H. Y., Cheng, F. W. T., et al. (2004) · Emerging infectious diseases · doi:10.3201/eid1003.030493 · Cited by 60
Shirato, K., Kawase, M., Watanabe, O., Hirokawa, C., Matsuyama, S., Nishimura, H., & Taguchi, F. (2012) · Journal of General Virology · doi:10.1099/vir.0.043117-0 · Cited by 43
Basic Problems of Serological Laboratory Diagnosis
Fierz, W. (1999) · Molecular Biotechnology · doi:10.1385/mb:13:2:89 · Cited by 27
Neurologic Manifestations of SARS-CoV-2, the Virus that Causes COVID-19
Naji, H. S. (2020) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2020.2.6.533 · Cited by 8
Cited by
Considerations for diagnostic COVID-19 tests
Vandenberg, O., Martiny, D., Rochas, O., van Belkum, A., & Kozlakidis, Z. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00461-z · Cited by 803
A comprehensive review of COVID-19 characteristics
Esakandari, H., Nabi-Afjadi, M., Fakkari-Afjadi, J., Farahmandian, N., Miresmaeili, S.-M., & Bahreini, E. (2020) · Biological Procedures Online · doi:10.1186/s12575-020-00128-2 · Cited by 510
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis
Rostami, A., Sepidarkish, M., Leeflang, M. M. G., Riahi, S. M., Nourollahpour Shiadeh, M., Esfandyari, S., Mokdad, A. H., Hotez, P. J., & Gasser, R. B. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.020 · Cited by 369
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
Curigliano, G., Banerjee, S., Cervantes, A., Garassino, M. C., Garrido, P., Girard, N., Haanen, J., Jordan, K., Lordick, F., Machiels, J. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.010 · Cited by 307
Funari, R., Chu, K.-Y., & Shen, A. Q. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112578 · Cited by 279
Metadata
- Authors
- Lee, C. Y.-P., Lin, R. T. P., Renia, L., & Ng, L. F. P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-24
- Volume
- 11
- Pages
- 879-879
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3020411887
- Cited by
- 260
- References
- 47
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.